Schedule 13D ownership disclosure

ANIKA THERAPEUTICS INC

Common Stock, par value $0.01 per share · CUSIP: 035255108

Event date: 2026-01-23

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Caligan Partners LPReported CIK 0001727492

    Shares: 1,435,130.00 · Class: 9.95%

  • David JohnsonReported CIK 0001785557

    Shares: 1,435,130.00 · Class: 9.95%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000902664-26-000511
Form type
SCHEDULE 13D/A
Filer
Anika Therapeutics, Inc.
CIK
CIK 898437
Filed
Jan 27, 2026
Reporting period
Jan 23, 2026
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub